Laura D. Carbone

Laura D. Carbone

Auto-generated profile, based on publicly available information

Laura D. Carbone

J. Harold Harrison is Distinguished University Chair in Rheumatology, Medical College of Georgia at Augusta University, 1120 15th St, Augusta, GA, 30912, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2004 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
LCLaura D. Carbone
Laura D. Carbone
MNMichael C. Nevitt
Michael C. Nevitt
KWKathryn Wildy
Kathryn Wildy
KBKaren D. Barrow
Karen D. Barrow
FHFran Harris
Fran Harris
HSHealth, Aging and Body Composition Study
Health, Aging and Body Composition Study
Objective: To examine the cross‐sectional association between use of medications that have a bone antiresorptive effect (estrogen, raloxifene, and alendronate) and both the structural features of knee osteoarthritis (OA), assessed by magnetic resonance imaging (MRI) and radiography, and the symptoms of knee OA in elderly women.Methods: Women in the Health, Aging and Body Composition Study underwent MRI and radiography of the knee if they reported symptoms of knee OA, and women without significant knee symptoms were selected as controls. MR images of the knee were assessed for multiple features of OA using the Whole‐Organ MRI scoring method, and radiographs were read for Kellgren and Lawrence grade and individual features of OA. Concurrent medication use and knee symptoms were assessed by interview, and knee pain severity was evaluated using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).Results: There were 818 postmenopausal women from whom we obtained MR images of the knee and data on medication use. Among these women, 214 (26.2%) were receiving antiresorptive drugs. We found no significant association between overall use of antiresorptive drugs and the presence of knee pain and radiographic changes of OA of the knee. Use of alendronate, but not estrogen, was associated with less severity of knee pain as assessed by WOMAC scores. Both alendronate use and estrogen use were associated with significantly less subchondral bone attrition and bone marrow edema–like abnormalities in the knee as assessed by MRI, as compared with women who had not received these medications.Conclusion: Elderly women being treated with alendronate and estrogen had a significantly decreased prevalence of knee OA–related subchondral bone lesions compared with those reporting no use of these medications. Alendronate use was also associated with a reduction in knee pain according to the WOMAC scores.

1 October 2003 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
LCLaura D Carbone
Laura D Carbone
FTFrances A Tylavsky
Frances A Tylavsky
JCJane A Cauley
Jane A Cauley
THTamara B Harris
Tamara B Harris
TLThomas F Lang
Thomas F Lang
SKStephen B Kritchevsky
Stephen B Kritchevsky
BMD was examined in users of NSAIDs (by COX selectivity) and aspirin in the Health ABC cohort (n = 2853). Significantly higher BMD was found in users of relative COX‐2 selective NSAIDs with aspirin (COX‐2/ASA) compared with nonusers. This suggests a role for COX‐2/ASA in osteoporosis. Introduction: The purpose of this study was to determine the relationship of nonsteroidal anti‐inflammatory drug (NSAID) use, by cyclo‐oxygenase selectivity (COX), and aspirin use on bone mineral density (BMD) in participants from the Health, Aging, and Body Composition (Health ABC) population‐based cohort. It is known that NSAIDs inhibit the COX enzyme and decrease production of prostaglandins, which are involved in regulation of bone turnover. COX has two isoforms, COX‐1 and COX‐2. Production of prostaglandins associated with bone loss is primarily mediated through the COX‐2 pathway. In addition, aspirin may have effects on bone independent of the prostaglandin pathway. Materials and Methods: NSAID (by COX selectivity) and aspirin use and BMD were assessed in 2853 adults (49.5% women, 50.5% men; 43.1% black, 56.9% white; mean age: 73.6 years) from the Health ABC cohort. For the purposes of this analysis, relative COX‐1 selective NSAIDs were defined as having a ratio of COX‐1 IC50 to COX‐2 IC50 of >1 in whole blood, and relative COX‐2 selective NSAIDs were defined as having a ratio of COX‐1 IC50 to COX‐2 IC50 of <1 in whole blood. Analysis of covariance was used to compare BMD across each NSAID use and aspirin use category adjusting for age, race, gender, weight, height, study site, calcium and vitamin D supplementation, Womac score, history of rheumatoid arthritis, history of arthritis other than rheumatoid, and smoking status. Results: After adjustment for possible confounders, current use of relative COX‐2 selective NSAIDs with aspirin was associated with higher BMD at the whole body (4.2%, 1.2–7.3 CI) and total hip (4.6%, 0.5–8.8 CI) by DXA and at both trabecular (34.1%, 15.4–52.7 CI) and cortical spine (12.8%, 2.3–23.3 CI) by quantitative computed tomography. Conclusions: Our data suggest that the combination of relative COX‐2 selective NSAIDs and aspirin is associated with higher BMD at multiple skeletal sites in men and women.

4 November 2009 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LCLaura Carbone
Laura Carbone
PBPetra Bůžková
Petra Bůžková
HFHoward A. Fink
Howard A. Fink
JLJennifer S. Lee
Jennifer S. Lee
ZCZhao Chen
Zhao Chen
JRJohn R. Robbins
John R. Robbins
The aim of the study was to find the epidemiology of hip fractures in heart failure. The increasing survival rate for patients with heart failure places them at risk for other diseases of ageing, including osteoporosis. We included 5613 persons from the Cardiovascular Health Study (CHS) with an average of 11.5 year follow-up. We determined incidence rates and hazard ratios (HRs) in persons with heart failure compared with persons without heart failure and mortality hazards following these fractures. Annualized incidence rates for hip fractures were 14 per 1000 person-years in heart failure and 6.8 per 1000 person-years without heart failure. Unadjusted and multivariable adjusted HRs for hip fracture associated with heart failure in men were 1.87 (95% CI 1.2–2.93) and 1.59 (95% CI 0.93–2.72), respectively. Respective HRs for women were 1.75 (95% CI 1.27–2.4) and 1.41 (95% CI 0.98–2.03). Mortality hazard was ∼2-fold greater in patients with heart failure and hip fracture compared with those having heart failure alone. Persons with heart failure are at high risk for hip fractures. However, much of the association between hip fractures and heart failure is explained by shared risk factors. Hip fractures are a substantial contributor to mortality in men and women with heart failure.

1 June 2008 in Metabolism
Verified
Journal Article
Closed access
LCLaura D. Carbone
Laura D. Carbone
ERE. William Rosenberg
E. William Rosenberg
ETElizabeth A. Tolley
Elizabeth A. Tolley
Michael HolickMichael Holick
Michael Holick
THThomas A. Hughes
Thomas A. Hughes
KWKarl T. Weber
Karl T. Weber

26 January 2009 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
LCLaura D. Carbone
Laura D. Carbone
KJKaren C. Johnson
Karen C. Johnson
ABAndrew J. Bush
Andrew J. Bush
JRJohn Robbins
John Robbins
JLJoseph C. Larson
Joseph C. Larson
ALAndrea Z. LaCroix
Andrea Z. LaCroix
Osteoporosis and heart failure are particular health concerns for women.1-3 Half of all postmenopausal women will experience an osteoporosis-related fracture in their lifetime.1,2 By the age of 40 years, the lifetime risk for women of developing heart failure is 1 in 5.3

10 May 2018 in The Journal of Spinal Cord Medicine
Verified
Journal Article
Closed access
NZNour Zleik
Nour Zleik
FWFrances Weaver
Frances Weaver
RHRobert L. Harmon
Robert L. Harmon
BLBrian Le
Brian Le
RRReshmitha Radhakrishnan
Reshmitha Radhakrishnan
LCLaura Carbone
Laura Carbone
Objectives: The primary objective was to review the literature regarding methodologies to assess fracture risk, to prevent and treat osteoporosis and to manage osteoporotic fractures in SCI/D. Study Design: Scoping review. Settings/Participants: Human adult subjects with a SCI/D. Outcome measures: Strategies to identify persons with SCI/D at risk for osteoporotic fractures, nonpharmacological and pharmacological therapies for osteoporosis and management of appendicular fractures. Results: 226 articles were included in the scoping review. Risk of osteoporotic fractures in SCI is predicted by a combination of DXA-defined low BMD plus clinical and demographic characteristics. Screening for secondary causes of osteoporosis, in particular hyperparathyroidism, hyperthyroidism, vitamin D insufficiency and hypogonadism, should be considered. Current antiresorptive therapies for treatment of osteoporosis have limited efficacy. Use of surgery to treat fractures has increased and outcomes are good and comparable to conservative treatment in most cases. A common adverse event following fracture was delayed healing. Conclusions: Most of the research in this area is limited by small sample sizes, weak study designs, and significant variation in populations studied. Future research needs to address cohort definition and study design issues.